Author

N. Francini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

D. L. Michell· 2 shared A. Cavnar· 1 shared A. G. Sorets· 1 shared C. DeJulius· 1 shared C. Duvall· 1 shared C. L. Duvall· 1 shared C. R. DeJulius· 1 shared E. Hoogenboezem· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

D. L. Michell

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Albumin-binding RNAi Conjugate for Carrier Free Treatment of Arthritis

J. M. Colazo, E. N. Hoogenboezem, M. C. Keech, N. Francini, V. Shah, F. Yu, J. H. Lo, A. G. Sorets, J. T. McCune, H. Cho, C. R. DeJulius, D. L. Michell, T. Maerz, K. C. Vickers, K. N. Gibson-Corley, , C. L. Duvall

This paper develops an MMP13-targeting siRNA conjugate that preferentially accumulates in arthritic joints, reducing disease markers and outperforming current treatments.

bioRxiv · May 31, 2023 · PreprintBioengineering

Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy

E. Hoogenboezem, S. S. Patel, A. Cavnar, J. Lo, L. Babb, N. Francini, P. Patil, J. Colazo, D. L. Michell, V. Sanchez, J. McCune, J. Ma, C. DeJulius, L. Lee, J. Rosch, , C. Duvall

This paper optimizes siRNA conjugates for albumin binding to enhance tumor delivery and efficacy in cancer therapy, achieving 80% MCL1 silencing and improved survival in breast cancer models.

bioRxiv · Feb 14, 2023 · PreprintBioengineering